Framingham, Mass., July 27, 2006-- GTC Biotherapeutics, Inc. (Nasdaq: GTCB) ("GTC") announced today that its financial results for the second quarter 2006 will be released on Thursday, August 3, 2006 before the Nasdaq market opens. Geoffrey F. Cox, Ph.D., Chairman of the Board, Chief Executive Officer and President, will lead the call on August 3 starting at 10:00 a.m. Eastern Time to discuss these results and the Company's drug development progress. You may access the live internet broadcast or the subsequent archived recording, on GTC's website at http://www.gtc-bio.com or as follows:
Live Call - In the United States, dial 1-800-599-9816
Outside the United States, dial 1-617-847-8705
Reference call ID: when prompted 24504992
Audio Archive - In the United States, dial 1-888-286-8010
Outside the United States, dial 1-617-801-6888
Reference call ID: when prompted 39271753
NOTE: a replay of the call will be available one hour following the end of the call and will be accessible until August 10, 2006.
The earnings webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.earnings.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com).
About GTC Biotherapeutics
GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC's lead program is ATrynŽ, its recombinant form of human antithrombin. The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion regarding GTC application for the use of ATrynŽ in patients with a hereditary antithrombin deficiency undergoing surgical procedures. In addition to the ATrynŽ program, GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors, and a malaria vaccine. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. One of the external programs is in clinical trials with a transgenically produced product. Additional information is available on the GTC web site, http://www.gtc-bio.com.
CONTACT:
GTC Biotherapeutics, Inc.
Thomas E. Newberry
Vice President, Corporate Communications
(508) 370-5374 Feinstein Kean Healthcare for GTC Biotherapeutics, Inc.
Francesca DeVellis (investors)
(617) 577-8110
Copyright 2006 GTC Biotherapeutics, All Rights Reserved